Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)
You Might Also Like Related content you may find interesting
Chronic stress can "shutdown" non-essential functions like digestion, leading to many of the symptoms people hope BPC-157 will fix
Peptide therapy for athletes Mumbai is available at The Sculptique Aesthetics with the same standards we apply to all our peptide protocols
US$ 23.30
US$ 21.71
US$ 26.91
US$ 28.77
